Introduction
============

The production of β-lactamases is the predominant cause of resistance to β-lactam antibiotics in Gram-negative bacteria ([@B2]), including the hyperproduction of plasmid-mediated TEM-1 β-lactamases, production of extended-spectrum beta-lactamases (ESBLs), plasmid-mediated AmpC enzymes ([@B4]) and carbapenem-hydrolyzing β-lactamases (carbapenemases)([@B29]; [@B16]). Combining β-lactam and a β-lactamase inhibitor (BLBLIs) was a common strategy to overcome resistance ([@B5]; [@B20]). However, resistance to BLBLIs has also been regularly observed ([@B21]; [@B28]).

TEM-1 was described in the early 1960s as the first plasmid-mediated β-lactamase in Gram-negative bacteria ([@B10]). Being plasmid and transposon-mediated has facilitated its spread to other species of bacteria and it is now the most commonly encountered β-lactamase in Gram-negative bacteria ([@B3]). The subgroups were defined and designated a, b, and c for a given *bla*~TEM~ gene derivative, because of their relation to a certain number of nucleotide differences in their structural gene sequence ([@B18]). The corresponding *bla*~TEM-1b~ gene derives from *bla*~TEM-1a~ by three base pair changes: C226T, C436T, and G604T, silent base pair change. *bla*~TEM-1c~ gene differs from *bla*~TEM-1a~ by the nucleotide substitution C436T, which is also silent. *bla*~TEM-2~ differs from *bla*~TEM-1a~ at position 317, where a A-to-C substitution leads to Gln39Lys ([@B14]). Previous studies identified four *bla*~TEM~ promoters: the weak *P3* promoter, and the strong promoters *Pa/Pb*, *P4*, and *P5* ([@B17]). *P3* corresponds to the promoter of the *bla*~TEM~ gene located in a Tn*2* or Tn*3* transposon ([@B26]; [@B17]; [@B19]). A single-base pair mutation (C32T) results in the stronger overlapping promoters *Pa/Pb*, first found upstream of the gene *bla*~TEM-2~, and produces larger amounts of the enzyme compared with the promoter *P3* ([@B6],[@B7]). Thus, an updated *bla*~TEM~ gene nomenclature was proposed on the basis of the sequences of structural *bla*~TEM~ genes and their promoters ([@B13]).

[@B17] assessed and compared the respective impact of the four promoters on β-lactam resistance. Among the recombinant plasmids, one with a *bla*~TEM-1b~ gene driven by a *Pa/Pb* promoter resulted in resistance to AMC and ticarcillin-clavulanate (TCC), but susceptibility to piperacillin-tazobactam (TZP) with a MIC value of 2 mg/L. In this study, the mechanism of TZP resistance was investigated in *Escherichia coli* RJ904, a clinical isolate containing the *bla*~TEM-1b~ gene with a *Pa/Pb* promoter. Experimental and genomic data support a role for *Pa/Pb* promoter regulation, leading to *bla*~TEM-1b~ hyperproduction, as the primary basis for TZP resistance in this isolate.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

This study was approved by the ethics committee of Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China and the Review Board exempted the requirement for written informed consent because this retrospective study only focused on bacteria and did not affect the patients.

Bacterial Strains and Growth Condition
--------------------------------------

The clinical strain *E. coli* RJ904 was obtained from the blood specimen of a hospitalized patient in Shanghai, China (Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University) in 2005. Ceftazidime was used for the medication. The patient's condition improved after the treatment and the patient was discharged. The isolate was identified using VITEK2 automated systems (BioMérieux, France). All of the plasmids used in this study are listed in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. All cloning procedures were carried out in *E. coli* (DH5α), and antibiotics were used with suitable concentrations for plasmid selection when necessary. All the *E. coli* strains were routinely grown in Luria-Bertani (LB) broth (Oxoid) and incubated overnight at 35°C.

Antimicrobial Susceptibility Testing
------------------------------------

Susceptibility testing of all the antibiotics for the clinical strain RJ904, transconjugant RJ904C, and recombinant vectors RJ904-PA/PB was determined using the *E*-test (bioMérieux, France). The antibiotic susceptibility of the strains to piperacillin with a fixed concentration of tazobactam (TZP, 4 mg/L) was determined using three methods: *E*-test, agar dilution, and broth microdilution method. The results were interpreted based on the guidelines of the [@B8].

Conjugal Transfer Experiments and S1-Nuclease Pulsed-Field Gel Electrophoresis (S1-PFGE)
----------------------------------------------------------------------------------------

Conjugal transfer experiments were performed in broth culture using the strain RJ904 as the donor and the sodium azide-resistant strain *E. coli* J53Azi^r^ as the recipient. Selection was performed with piperacillin (100 mg/L), tazobactam (4 mg/L), and sodium azide (100 mg/L). The plasmid DNA of RJ904 and its transconjugant RJ904C was examined using S1-PFGE as previously described ([@B1]).

Plasmid Construction
--------------------

The principle features of all plasmids are listed in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}.

First, the fragment of *bla*~TEM-1b~ gene was screened by the shortgun cloning. In brief, plasmid DNAs of pRJ904 were extracted with the Plasmid DNA Mini Kit (Omega). pRJ904 and the clone vector pACYC184 were digested with restriction enzymes *BamH*I and *Hind*III (Thermo Fisher Scientific) and ligated to construct a DNA library, which was used to transform the competent cells. Selection was then performed with piperacillin (100 mg/L), tazobactam (4 mg/L), and chloramphenicol (50 mg/L). The new cloned plasmid was named pRJ904-PA/PB.

The recombinant vector was cloned as described by [@B17] using the same primers (BamHI-P-F and BamHI-P-R), clone vector, and restriction enzyme digestion site. pRJ904-PA/PB and p749 (MH491004) served as templates, respectively. p749 was a plasmid from *E. coli* retained by our laboratory that contained the *bla*~TEM-1b~ gene and promoter region with 99% base pair identity to pRJ904, except a point mutation (T32C) in the promoter region of *bla*~TEM-1b~, resulting in substitution of the promoter *Pa/Pb* for *P3*. The PCR products were purified and digested with *BamH*I (Thermo Fisher Scientific) and cloned into pACYC184 to construct plasmids pRJ904-PA/PB-P and pRJ904-P3-P. Both plasmids were cloned based on pACYC184, and the *bla*~TEM-1b~ gene was inserted; however, pRJ904-PA/PB-P contained the *Pa/Pb* promoter while pRJ904-P3-P contained the *P3* promoter.

After cloning, all of the plasmids were transformed into *E. coli* DH5α cells by using standard techniques ([@B11]). Selection was performed on an LB agar plate containing ampicillin (100 mg/L) and chloramphenicol (50 mg/L). Proper integration of all the constructs were verified by PCR amplification with the primers 184-F and 184-R binding on pACYC184, followed by sequencing of the PCR product. The direction of the *bla*~TEM-1b~ fragments in all the constructs were opposite to the *tetR* gene of pACYC184 in order to rule out the possible expression of the *tetR* gene.

Transcriptional Analysis of *bla*~TEM-1b~
-----------------------------------------

For real-time PCR, the indicated *E. coli* strains were grown in LB broth and harvested at an OD600 of 1. The RNA was extracted using RNeasy Mini Kit (Qiagen), and then used to generate cDNA with PrimeScript^TM^ RT Master Mix (TaKaRa). RT-PCR was performed using SYBR green PCR master mix (Applied Biosystems) with the primer pair TEM-F and TEM-R ([Supplementary Table S2](#SM1){ref-type="supplementary-material"}) on a cobas z480^®^ system (Roche) ([@B15]). Amplification of the 16S rRNA gene (as an endogenous control) was performed to standardize the amount of sample RNA or DNA added to a reaction. Relative quantification was determined by the 2^-ΔΔCT^ method. Each assay was performed in triplicate with three independent cultures. Statistical comparisons were performed by one-way analysis of variance (ANOVA) followed by Holm-Sidak tests to compare selected data pairs. Values of *P* \< 0.05 were considered statistically significant.

Nucleotide Sequence Accession Number
------------------------------------

The nucleotide sequence containing a *bla*~TEM-1b~ gene with the promoter *Pa/Pb* from the clinical strain RJ904 has been deposited in the GenBank sequence database under accession number [MH357372](MH357372).

Results
=======

Plasmid-Mediated Transfer of the Resistance to β-Lactam and β-Lactamase Inhibitor Combinations
----------------------------------------------------------------------------------------------

The clinical isolate RJ904 was determined by *E*-test and found to be highly resistant to BLBLIs, including AMC, TCC, and TZP (MICs\>256 mg/L), but was susceptible to third-generation ([Table 1](#T1){ref-type="table"}). Resistance to TZP was transferable using the broth mate conjugation assay. Although the transconjugant RJ904C showed a decreased MIC to third-generation cephalosporins, the MIC values of BLs and BLBLIs were all significantly higher than that of the recipient strain *E. coli* J53Azi^r^. The results of S1-PFGE confirmed the presence of a ca. 100 kb plasmid in both the donor strain RJ904 and the transconjugant RJ904C ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}).

###### 

Antibiotic susceptibilities of *E. coli* strains RJ904, RJ904C, RJ904-PA/PB, RJ904-P3.

  Antibiotics               MIC (mg/L)                           
  ------------------------- ------------ ------- ------- ------- -------
  Amoxicillin               4            4       \>256   \>256   \>256
  Piperacillin              2            2       \>256   \>256   \>256
  Amoxicillin-clavulanate   4            2       \>256   \>256   \>256
  Ticarcillin-clavulanate   2            1       \>256   \>256   \>256
  Piperacillin-tazobactam   1            0.5     \>256   \>256   \>256
  Cefazolin                 4            4       \>256   \>256   \>256
  Cefuroxime                4            4       32      4       8
  Cefoperazone              0.125        0.064   \>256   32      256
  Cefotaxime                0.032        0.032   0.5     0.064   0.25
  Ceftazidime               0.125        0.125   2       0.5     2
  Cefoxitin                 4            4       64      4       4
                                                                 

Hyperproduction of TEM-1b β-Lactamase Mediated by the Promoter *Pa/Pb*
----------------------------------------------------------------------

The shortgun cloning and sequence analysis revealed that the recombinant vector pRJ904-PA/PB contained a DNA insertion of approximately 3.9 kb containing the *bla*~TEM-1b~ gene, located on the resolvase gene (*tnpR*) of Tn2, and the promoter upstream the *bla*~TEM-1b~ gene was *Pa/Pb* ([Figure 1](#F1){ref-type="fig"}). The MIC value of BLs and BLBLIs of *E. coli* RJ904-PA/PB was similar to that of the transconjugant RJ904C ([Table 1](#T1){ref-type="table"}).

![Schematic representation of the 3.9-kb *BamH*I and *Hind*III-digested embedded TEM-1b fragment (black arrow) and the promoter *Pa/Pb* (white rectangle). Truncated *tnpA* of Tn2 was placed on both sides of the resistance gene (gray). The sites for primers BamHI-P-F and BamHI-P-R for PCR clone are also indicated.](fmicb-10-00833-g001){#F1}

The level of *bla*~TEM-1b~-specific transcription was determined by quantitative RT-PCR. As shown in [Figure 2](#F2){ref-type="fig"}, RJ904-PA/PB demonstrated a significantly higher relative *bla*~TEM-1b~ expression level than RJ904-P3-P (*P* \< 0.01).

![Relative *bla*~TEM-1b~ expression levels of all the strains. ^∗^*p* \< 0.01. RJ904-P3-P served as a reference. RJ904-PA/PB and RJ904-PA/PB-P also demonstrated a significantly higher *bla*~TEM-1b~ expression level than RJ904-P3-P.](fmicb-10-00833-g002){#F2}

Expression of TEM-1b for pRJ904-PA/PB-P and pRJ904-P3-P
-------------------------------------------------------

To further confirm that the resistance to TZP is caused by the promoter *Pa/Pb* and for comparison with the results of [@B17], the plasmids pRJ904-PA/PB-P and pRJ904-P3-P were constructed.

The MIC value of TZP for all strains was determined by three different methods ([Table 2](#T2){ref-type="table"}). The MIC values of RJ904-PA/PB and RJ904-PA/PB-P were \>256 mg/L in the *E*-test and were ≥024 mg/L in agar dilution and broth microdilution tests, indicating no difference from the susceptibility profile of the original strain RJ904 and the transconjugant RJ904C. However, RJ904-P3-P demonstrated significantly declined MIC values of 8 mg/L (agar dilution and *E*-test) or 16 mg/L (broth microdilution test), and 4 mg/L (agar dilution and *E*-test) or 8 mg/L (broth microdilution test), respectively. Consistently, RJ904-PA/PB-P demonstrated a significantly higher *bla*~TEM-1b~ expression level than RJ904-P3-P.

###### 

Susceptibility testing results of *E. coli* strains to piperacillin with 4 mg/L of tazobactam (TZP).

  Strain          *E*-test (mg/L)^a^   Agar dilution (mg/L)   Broth microdilution (mg/L)
  --------------- -------------------- ---------------------- ----------------------------
  ATCC25922       2                    2                      1
  J53             1                    1                      1
  DH5α            0.5                  1                      2
  RJ904           \>256                ≥1024                  ≥1024
  RJ904C          \>256                ≥1024                  ≥1024
  RJ904-PA/PB     \>256                ≥1024                  ≥1024
  RJ904-PA/PB-P   \>256                ≥1024                  ≥1024
  RJ904-P3-P      4                    4                      8
                                                              

a

MIC breakpoint (mg/L):

S

≤ 16/4; I: 32/4--64/4;

R

≥ 128/4 (CLSI).

Discussion
==========

The conjugation experiment demonstrated that resistance to TZP can be transferred from RJ904 to J53Azi^r^. The short gun method was used to screen out a strain that was highly resistant to TZP, and sequence analysis revealed that the plasmid harbored a 3.9-kb insertion embedded in the *bla*~TEM-1b~ gene with the strong promoter *Pa/Pb*. The mutant strain RJ904-P3-P with the weak promoter *P3* demonstrated substantially declining MIC values to TZP. Moreover, RJ904-PA/PB and RJ904-PA/PB-P demonstrated a higher *bla*~TEM-1b~ expression level than RJ904-P3-P. Altogether, these data provide strong functional evidence that the acquisition of TZP resistance was due to the hyperproduction of TEM-1b β-lactamases mediated by the strong promoter *Pa/Pb*.

[@B17] suggested that the *bla*~TEM-1b~ gene with a *Pa/Pb* promoter could contribute to the resistance to AMC and TCC but not to TZP with a MIC value of 2 mg/L, suggesting the potential importance of this promoter for β-lactam resistance. However, we found that strain RJ904-PA/PB, which also contained the *bla*~TEM-1b~ gene with a *Pa/Pb* promoter, was highly resistant to TZP with a MIC value \>256 mg/L. To identify possible causes of the difference, we replicated the experiment of [@B17] using the exact same primers, clone vector, and restriction enzyme digestion site to clone the plasmid with the *bla*~TEM-1b~ gene and *Pa/Pb* promoter (pRJ904-PA/PB-P), which was compared to a plasmid with the *P3* promoter (pRJ904-P3-P). We next determined the MIC value of TZP of all strains. Since several authors have claimed that the MIC determination of TZP can be method-dependent and strains exhibited discordant behavior and heterogeneous resistance in different methods ([@B9]; [@B23]), we used three methods for susceptibility testing to avoid the methodological impact: broth microdilution, agar dilution, and *E*-test. Several studies have compared the results of TZP susceptibility testing with broth microdilution and agar dilution methods for isolates of various species,([@B27]; [@B9]; [@B25]; [@B23]) and broth microdilution showed a tendency toward higher MIC values than agar dilution ([@B25]). In the present study, there was no difference in the MIC values of RJ904-PA/PB-P to those of strains RJ904, RJ904C, and RJ904-PA/PB regardless of the method used. All these strains with a promoter *Pa/Pb* demonstrated high resistance to TZP unlike Lartigue's transformants, while strains with a promoter *P3* (RJ904-P3 and RJ904-P3-P) demonstrated a significantly declined MIC value ultimately becoming susceptible to TZP, which is consistent with the findings of Lartigue's transformants with a *P3* promoter. *E. coli* DH5α was used as the recipient rather than *E. coli* NM554. However, RJ904, the transconjugant RJ904C (*E. coli* J53), and RJ904-PA/PB-P (*E. coli* DH5α) all demonstrated high resistance to TZP. These results indicate that the recipient will not have a great impact on the expression of drug-resistant genes.

Nevertheless, when we repeated the experiment, we reached a different conclusion. The strains with promoter *Pa/Pb* in our study demonstrated high resistance to TZP while Lartigue's transformants was susceptible to TZP. Although the reason for this discrepancy is not yet clear, our results from several independent assessments all indicate that the resistance to TZP was due to hyperproduction of TEM-1b β-lactamases mediated by the strong promoter *Pa/Pb*. However, overexpression of *bla*TEM-1 can lead to resistance, including clavulanate and sulbactam ([@B24]; [@B28]). *bla*~TEM-1~ hyperproduction resulting from an increase in *bla*~TEM-1~ gene dosage has also been documented ([@B30]; [@B28]). [@B22] claimed that tandem *bla*~TEM-1~ gene amplification, leading to *bla*~TEM-1~ hyperproduction, as the primary basis for TZP resistance in *E. coli*. These results indicated that *bla*~TEM-1~ hyperproduction can lead to BLBLIs resistance, including TZP.

Whole-genome sequencing (WGS) can help to infer antimicrobial susceptibility accurately using a single assay ([@B12]). However, most existing databases focus only on the commonly known resistance loci while neglecting the role of promoters. Our finding should be considered for the acquisition of more accurate WGS-inferred bacterial antimicrobial susceptibility testing. Importantly, these data add to the growing body of evidence that the same resistance gene with different promoters will result in completely different susceptibility testing results. Thus, when performing WGS-inferred AST, we should not only assess the resistance genes but should also analyze their promoter sequences simultaneously. Our finding also shed light on the possibility of a fast identification using a simple PCR and sequencing to identify strong promoters and weak promoters and to infer antimicrobial susceptibility.
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